Implandata Announces Successful Implantation of Micro-Sensor for Intraocular Pressure Measurement in Glaucoma Patient

Implandata logo

Hannover, Germany, June 24, 2014 / B3C newswire / -  Implandata Ophthalmic Products GmbH (Implandata) reports the successful implantation of the first patient within the ARGOS-02 clinical study at Augenklinik Bellevue in Kiel, Germany.  In the ARGOS-02 clinical study, six eye centers in Germany (see further information at: are currently recruiting primary open angle glaucoma patients, undergoing cataract extraction. These patients are eligible to receive the implantable micro sensor for wireless intraocular pressure measurement.

During cataract surgery Implandata’s intraocular pressure sensor is placed in front of the artificial intraocular lens, posterior to the iris. After implantation of the micro sensor the patient’s intraocular pressure measurements can be measured at any chosen frequency, either continuously over the course of 24 hours or on demand at certain times. Patients can perform measurements by themselves and under normal live conditions. Collected data will be sent via a mobile phone module to the eye doctor’s computer screen, allowing him to remotely monitor and manage the patient’s disease.

“So far the first results of this innovative product are very compelling“, concludes Prof. Dr. med. Detlef Uthoff, Medical Director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient”, explains Prof. Uthoff.

Implandata’s intraocular pressure sensor allows close monitoring of the patients disease status and glaucoma therapy success. Through simple and more frequent measurements of intraocular pressure - which is the key parameter in glaucoma therapy - important information on therapy response is delivered to the eye doctor early on, enabling immediate glaucoma therapy adjustment, contributing to prevention of further vision loss due to uncontrolled intraocular pressure.

In the ongoing ARGOS-02 study Implandata will generate sufficient data to approach the CE conformity process for intraocular placement of the micro sensor in 2015. Currently the product is not CE marked or FDA approved. But Implandata is planning to conduct in foreseeable future additional clinical studies in Europe and the USA in order to validate various product versions for various glaucoma patient situations.

About Implandata Ophthalmic Products GmbH
Implandata Ophthalmic Products GmbH is a privately held medical device company founded in 2010 and headquartered in Hannover, Germany. Implandata’s product for continuous monitoring of intraocular pressure will transform management of glaucoma patients, providing dramatically improved quality and quantity of intraocular pressure data, which is key for personalized therapy and therapy control. Remote patient management will increase glaucoma treatment efficiency and results in cost savings for all stakeholders.


Max G. Ostermeier
Implandata Ophthalmic Products GmbH
Kokenstrasse 5
30159 Hannover
Phone: +49 551 2204 2581
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.